About: Ammonium tetrathiomolybdate is a(n) research topic. Over the lifetime, 187 publication(s) have been published within this topic receiving 4249 citation(s).
Papers published on a yearly basis
01 Mar 2012
TL;DR: There is not a single randomized controlled trial conducted in Wilson's disease which has an optimal design so it is impossible to assign a high or even a moderate quality of evidence to any of the questions dealt with in these guidelines.
Abstract: This Clinical Practice Guideline (CPG) has been developed to assist physicians and other healthcare providers in the diagnosis and management of patients with Wilson's disease. The goal is to describe a number of generally accepted approaches for diagnosis, prevention, and treatment of Wilson's disease. Recommendations are based on a systematic literature review in the Medline (PubMed version), Embase (Dialog version), and the Cochrane Library databases using entries from 1966 to 2011. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system used in other EASL CPGs was used and set against the somewhat different grading system used in the AASLD guidelines (Table 1A and B). Unfortunately, there is not a single randomized controlled trial conducted in Wilson's disease which has an optimal design. Thus, it is impossible to assign a high or even a moderate quality of evidence to any of the questions dealt with in these guidelines. The evaluation is mostly based on large case series which have been reported within the last decades.
02 Apr 2011-Topics in Catalysis
TL;DR: In this article, three alkyltrimethylammonium thiomolybdates were used as precursors for in situ prepared MoS2 catalysts, activated during the hydrodesulfurization of dibenzothiophene.
Abstract: Three alkyltrimethylammonium thiomolybdates, [R–N(CH3)3]2MoS4 (where R = lauryl, myristyl or cetyl) were synthesized in aqueous solution, and characterized by 1H-NMR spectroscopy. These alkyltrimethylammonium thiomolybdates were used (the lauryl and myristyl thiomolybdates for the first time) as precursors for in situ prepared MoS2 catalysts, activated during the hydrodesulfurization of dibenzothiophene. The catalysts were analyzed by EDX, showing large voids and a S/Mo ratio around 2. High surface areas up to 443 m2/g and type IV adsorption–desorption nitrogen isotherms were obtained. X-ray diffraction showed that the catalysts are poorly crystalline, with a very weak (002) peak intensity for all samples except the MoS2 catalyst prepared from pure ammonium tetrathiomolybdate precursor. A high dibenzothiophene conversion (74%) was observed with the catalyst obtained from the lauryltrimethylammonium thiomolybdate precursor, attributed mainly to its high specific surface area. Selectivity results showed that all the prepared catalysts strongly favored the hydrogenation pathway.
TL;DR: In this paper, X-ray photoelectron spectroscopy (XPS) has been used for the preparation of ammonium tetrathiomolybdate (ATOM) solution.
Abstract: Preparation of MoS 2 by acidification of ammonium tetrathiomolybdate solution has been studied by X-ray photoelectron spectroscopy (XPS). The precipitates formed from the solution are mainly composed of MoS 3 , the Mo 3d chemical shift of which is approximately 4.2eV. Heat treatments of the above product at 450 and 850°C, in a vacuum of 1.33 × 10 −4 Pa, lead largely to formation of MoS 2 , with typical chemical shifts of abouth 1.2eV. The MoS 2 formed consists of nano-sized, crystalline particles of hexagonal (2H-type) structure. The validity of MoS 2 formation by this route is confirmed by comparative study, namely the decomposition of ATT solids under the same respective heat treatment conditions. Apart from these main aspects, origins of minor XPS peaks are also considered.
01 Jan 1991-JAMA Neurology
TL;DR: Results are presented from six patients treated with tetrathiomolybdate for up to 8 weeks as initial therapy with Wilson's disease, and none of the five patients who had presented with acute neurological symptoms worsened.
Abstract: Patients with Wilson's disease who present with acute neurological symptoms often become clinically worse when initially treated with penicillamine. Other available anticopper drug therapies do not appear to offer a solution to this treatment problem. We are developing and evaluating a new drug, ammonium tetrathiomolybdate for this purpose. Theoretically, tetrathiomolybdate has optimal properties, including an immediate blockade of copper absorption and the property of forming complexes with copper in the blood, rendering the copper nontoxic. In this article, we present results from six patients treated with tetrathiomolybdate for up to 8 weeks as initial therapy. None of the five patients who had presented with acute neurological symptoms worsened. Also presented are methods of assay, preliminary stability studies, and methods of evaluating therapeutic end points with respect to copper metabolism.
TL;DR: In this article, a simple strategy to synthesize the hierarchical MoS2/Ti3C2Tx hybrid by combining liquid nitrogen-freezing and subsequent annealing was reported.
Abstract: Developing highly efficient noble-metal-free electrocatalysts for hydrogen evolution reaction (HER) has attracted increasing attentions. Here, we report a simple strategy to synthesize the hierarchical “nanoroll” like MoS2/Ti3C2Tx hybrid by combining liquid nitrogen-freezing and subsequent annealing. The quick freezing of the Ti3C2Tx nanosheets and ammonium tetrathiomolybdate mixture causes a sudden change in the strain of Ti3C2Tx, which leads to an interesting “nanoroll” like hierarchical structure. After annealing at H2/Ar atmosphere, vertically aligned molybdenum sulfide (MoS2) crystallites are in situ formed in and on the nanoroll like Ti3C2Tx. Notably, this hierarchical MoS2/Ti3C2Tx hybrid exhibits excellent HER catalytic activity with a small onset overpotential of 30 mV, and a more than 25-fold increase in the exchange current density compared with MoS2 was observed.
Related Topics (5)
400.9K papers, 8.7M citations
85.9K papers, 2.6M citations
43.7K papers, 1.3M citations
67K papers, 2.1M citations
69.8K papers, 1.2M citations